Ionis has five FDA-approved drugs and promising upcoming approvals. See more about IONS stock and why it warrants a Buy ...

It is also looking to expand its RNA silencing research, potentially bringing it into competition with biotech heavyweights such as Alnylam, something that Mortazavi focused on during his long ...

Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...

Recombinant proteins are crucial in pharmaceutical and other industries. A production method uses plants as hosts in ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Small interfering RNA (siRNA) molecules hold immense potential for treating diseases by silencing specific genes. Encapsulated in lipid nanoparticles (LNPs), siRNA can be delivered efficiently to ...

Wave Life Sciences is a clinical-stage biotechnology company based in Cambridge, MA, dedicated to unlocking the potential of RNA medicines to transform human health. With a robust pipeline focused on ...

This valuable study addresses potential roles of the master regulator of X chromosome inactivation, the Xist long non-coding RNA, in autosomal gene regulation. Using data from mouse cells, the authors ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

Drs. Gary Ruvkun and Victor Ambros have been honored for their critical work in discovering the essential role of very small ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024 ...